Section Arrow
Quote
STRO.NASDAQ
- Sutro Biopharma
(Financial Status)
Quotes are at least 15-min delayed:2025/09/12 00:05 EDT
Regular Hours
Last
 0.97
+0.0596 (+6.55%)
Day High 
1.01 
Prev. Close
0.9104 
1-M High
1.18 
Volume 
478.10K 
Bid
0.9103
Ask
0.9506
Day Low
0.91 
Open
0.9178 
1-M Low
0.76 
Market Cap 
77.18M 
Currency USD 
P/E -- 
%Yield -- 
10-SMA 0.96 
20-SMA 0.9 
50-SMA 0.84 
52-W High 4.8 
52-W Low 0.5231 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-2.51/0.09
Enterprise Value
92.85M
Balance Sheet
Book Value Per Share
-0.38
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
62.04M
Operating Revenue Per Share
0.67
Industry Comparison
More
Code Name   Last Change Change (%) P/E P/E Range
GRIGRI Bio Inc.2.05+0.49+31.41%0.02PE
RXRXRecursion Pharmaceuticals4.85+0.31+6.83%-- 
SLXNSilexion Therapeutics Corp4.93+0.445+9.92%-- 
ADAPAdaptimmune Therapeutics plc0.0505-0.0003-0.59%-- 
ROIVRoivant Sciences Ltd14.41+0.64+4.65%1.95PE
Quotes are at least 15-min delayed：2025/09/12 00:05 EDT
Industry overview quotes are at least 15 minutes delayed
Business Description
Sutro Biopharma Inc is a clinical-stage drug discovery, development, and manufacturing company. It is mainly engaged in the development of biopharmaceutical products. The company manufactures next-generation protein therapeutics for cancerand autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and non-Hodgkin lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers. The company also pipeline contains STRO-004, STRO-006, STRO-00X, STRO-00Y, STRO-003, VAX24, VAX31, and Others.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.